Newsroom

austin, texas – immunoprecise antibodies ltd. (nasdaq: ipa) today announced the launch of its ai-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. by combining advanced artificial intelligence with first-principles thinking, the biostrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. ipa’s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. this mindset led to the creation of lensai, ipa’s proprietary ai platform, which organizes vast biological datasets into a unified framework, eliminating silos and accelerating discoveries. the ipa pipeline introduces a new era of ai-enhanced therapies designed to meet modern medical demands while addressing critical unmet needs. by pairing cutting-edge computational insights with rigorous lab validation, ipa ensures the delivery of treatments that are not only groundbreaking but also highly effective and reliable. powered by lensai's in silico workflows, the pipeline integrates data with precision at every stage of development, enabling therapies that are faster, more targeted, and impactful for the future of medicine. "our ai-powered pipeline represents a major leap forward for ipa," said dr. jennifer bath, ceo of immunoprecise antibodies. "by harnessing ai and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. this pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose." this launch marks a pivotal moment for ipa as it continues to set new standards in biotherapeutics. by tackling complex therapeutic challenges and addressing some of the world’s most pressing medical needs, ipa is poised to lead the next wave of ai-powered drug discovery. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the ai-driven pipeline, the potential for ai-enhanced therapeutic assets to accelerate drug discovery, and the company’s ability to develop and commercialize new therapeutic candidates. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

victoria, british columbia, june 12, 2024 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, today announces that its subsidiary, biostrand, has been honored with the prestigious 2024 impact award, sponsored by intersystems. this recognition highlights biostrand’s groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the industry. the 2024 impact award acknowledges biostrand’s innovative lensai technology, selected from over 1,000 client projects for its remarkable contributions. the selection committee, chaired by professor roberto zicari, identified biostrand’s work based on three key criteria: makes a significant difference: lensai’s innovative approach has substantially advanced the field of biotherapeutics. breaks new ground: the technology introduces novel methods and solutions, pushing the boundaries of current research and development. sets an example: biostrand’s achievements serve as a benchmark for other organizations, demonstrating excellence in innovation. the award will be presented today at the intersystems annual global summit, at the gaylord national resort and convention center in maryland, usa. this premier event attracts industry leaders and top professionals from around the globe, including c-level executives, subject matter experts, visionary leaders, managers, directors, and developers. this year’s summit expects over 1,200 attendees from more than 28 countries. the award celebration will take place today, from 10:30-11:00 am et, during a personalized award presentation session. the event offers an additional excellent opportunity for biostrand and ipa to showcase their innovative contributions to a global audience. “we are incredibly proud of biostrand’s achievements and this recognition from intersystems,” said dr. jennifer bath, ceo of immunoprecise antibodies ltd. “the impact award underscores the significance of biostrand’s pioneering work and reinforces our commitment to driving innovation in biotherapeutic research.” for more information about the intersystems global summit, the impact award, and to view dr. van hyfte’s formal acceptance of the award please visit today’s live stream starting at 9am et, at the intersystems global summit 2024: https://www.linkedin.com/events/7203844810565111808/about/ about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a leader in ai-driven biotherapeutic research and technology, providing comprehensive solutions for the discovery, development, and optimization of therapeutic antibodies. through its subsidiaries, including biostrand, immunoprecise leverages advanced technologies to accelerate the development of novel biotherapeutics. about biostrand biostrand, a subsidiary of immunoprecise antibodies ltd., specializes in innovative biotherapeutic research and development. biostrand’s lensai technology represents a groundbreaking approach in the field, driving significant advancements and setting new standards for innovation. investor contact: investors@ipatherapeutics.com   forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, biostrand®, has published a preprint of its groundbreaking white paper titled, "new paradigm for biological sequence retrieval inspired by natural language processing and database research" on biorχiv. the publication delves into the intricacies of one of biostrand’s applications based on its patented hyft-based methodology, a novel and proprietary approach to biological sequence retrieval, and its clear advantages over the gold standard algorithm, basic local alignment search tool “blast”. by detailing their innovative approach and its potential implications for the scientific community, biostrand aims to foster collaboration and drive innovation in the realm of bioinformatics. key highlights from the white paper: introduction to hyft patterns: the paper introduces hyft patterns as unique signature sequences, akin to biological fingerprints, found in amino acids, dna, and rna. these patterns serve as a tool to tokenize and harmonize all biological data into a unified omics language. parsing and indexing with hyfts: the paper details the two-step process of parsing biological sequences to retrieve hyft patterns and then indexing them. this approach prioritizes non-overlapping hyfts with lower ranks, ensuring comprehensive coverage of the sequence. benchmarking results: a comparative study between blast and the hyft methodology revealed that while blast excels in retrieving distant homologous sequences, hyft is particularly relevant for higher identity matches. dirk van hyfte, md, phd, co-founder and head of innovation of biostrand, remarked, "the publication of our research on biorxiv.org is not just a milestone for biostrand, but a significant contribution to the bioinformatics community. we believe, given the ever-increasing availability of sequence data, our hyft-based sequence similarity search methodology offers the scalability needed in this era of big data without losing precision, and we eagerly anticipate the discourse and collaboration it will inspire." lensai: the next-generation advanced ai platform recently, biostrand successfully rolled out its next-generation unified knowledge graph-large language model (llm) framework for holistic life sciences research. at the core of their lensai platform is a comprehensive and continuously expanding knowledge graph that maps a remarkable 25 billion relationships across 660 million data objects, linking sequence, structure, function, and literature information from the entire biosphere. their first-in-class technology provides a comprehensive understanding of the relationships between genes, proteins, structures, and biological pathways, thereby opening powerful new opportunities for drug discovery and development. the platform leverages the latest advances in ontology-driven nlp and ai-driven llms to connect and correlate syntax (multi-modal sequential and structural data) and semantics (biological functions). biostrand’s unified approach to biomedical knowledge graphs, retrieval augmented generation (rag) models, and llms combines the reasoning capabilities of llms, the semantic proficiency of knowledge graphs, and the versatile information retrieval capabilities of rag, to streamline the integration, exploration, and analysis of biomedical data, potentially unlocking a realm of uncharted possibilities. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

company received official notice from the european patent office (epo) for the decision to grant its patent application on april 5th, 2023. the patent was initially filed february 7th, 2020. patent application covers a method to efficiently handle mass biological sequence information. related patents pending in other countries, favorable outcomes anticipated victoria, british colombia march 27, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), the parent company of biokey and affiliate of biostrand, announced today that the epo has issued a “decision to grant” for biokey’s patent application covering the company’s hyft® technology used to organize and analyze biological sequence information. the hyft technology and methodology provide a novel way to efficiently tap into sequence information, allowing the extraction and use the relevant information therein to address the current problems in omics data integration and analysis. the hyft technology serves as the core of the biostrand’s lensai integrated technologytm platform which provides cutting-edge data solutions and antibody discovery. the patent will provide biostrand’s lensai integrated technology with broad protection, further strengthening the company’s patent portfolio position and enabling exclusive access to the hyft technology. the company anticipates favorable outcomes in other countries as well, as many patent offices worldwide consider the status of related european cases to be highly relevant to the decision to grant patents. “this is a significant and exciting decision by the epo, and we view this announcement as a recognition of biostrand’s important contributions to the fields of omic data integration and analysis, fields paramount to the future of cancer research, precision medicine, biomarker identification, and novel drug discovery and development,” stated dr. jennifer bath, ceo of ipa. “this patent provides protection for biokey’s hyft technology, which will give scientists the ability to advance the development of safer and more effective therapies for the toughest medical challenges we face today.” the hyft technology hyft technology is a way of organizing information about the natural world by creating connections between patterns found in living things, called hyfts. these patterns can link genetic sequences to their structures and functions, as well as to other information such as scientific papers and medical records. the output, the hyft knowledge graph, contains over 660 million patterns and 25 billion connections, and is continuously updated with new information. this provides a powerful tool for exploring relationships in the natural world, which can be used for research and applications in medicine and other fields. the hyft graph is unique in its explicit representation of information from the whole biosphere, and it provides a transparent intermediate layer between sequences and predictions that allows for new knowledge to be extracted without the limitations of a black box. hyft-based technologies have numerous applications in various fields beyond just data integration, organization, and analysis, such as drug immunogenicity testing, drug discovery, and natural language processing (nlp). these applications have the potential to accelerate the drug development process and improve patient outcomes. in the field of immunogenicity, hyfts can help predict parts of a molecule that may trigger an immune response. this information is crucial in therapeutic and vaccine development, as it helps identify potential safety concerns before they become problematic. moreover, hyfts can predict off-target effects, which occur when a drug or therapy affects unintended targets in the body. early identification of potential off-target effects allows researchers to design safer and more effective treatments. in drug discovery, hyft-based technologies have multiple potential applications, including: toxicity prediction: by linking genetic sequences to toxicological data, hyfts can predict the toxicity of potential drug candidates, helping researchers identify compounds likely to cause adverse effects before entering clinical trials. drug repurposing: hyfts can identify existing drugs for repurposing by linking genetic sequences to known targets and functions, accelerating the drug discovery process by finding compounds already approved for other indications. clinical trial design: hyfts can optimize clinical trial design by linking genetic sequences to patient data and clinical outcomes, identifying patient subgroups more likely to benefit from specific treatments, and enabling personalized and efficient clinical trials. biomarker discovery: by linking genetic sequences to disease-specific phenotypes, hyfts can identify biomarkers of disease, helping to identify at-risk patients and enable earlier diagnosis and treatment. another application of hyft-based technologies is tied to nlp, which involves analyzing and extracting information from written or spoken language. hyfts can link text-based information, such as scientific papers or medical records, to specific genetic sequences or structures, facilitating more efficient and accurate analysis. this is particularly valuable in genomics and personalized medicine, where vast amounts of textual data must be processed and analyzed to identify potential therapies or treatments. the company believes that the utilization of hyft-based technologies in drug discovery and other fields shows great promise for expediting the drug development process and enhancing patient outcomes. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, biokey bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the potential applications of hyft-based technologies and the prediction capabilities and speed of the discovery processes. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above-mentioned hyfts may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies